创胜集团 - 全整合型国际化生物制药公司

创胜集团, 生物药, 抗体, 药物研发

创胜集团 - 全整合型国际化生物制药公司

加入我们 联系我们

媒体报道

媒体报道

Temasek-backed Transcenta mulls HK-China dual IPO listing

2020 年 01 月 13 日

After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.

It’s been almost two years since the Stock Exchange of Hong Kong (HKG) permitted the public listing of biotech issuers without a track record of profitability. To date, 14 companies in that sector have taken the plunge, of which nine listed in 2019.

Another one to the list looks very likely to be Transcenta. The Suzhou-headquartered biotherapeutics company, which has yet to turn a profit but has raised $230 million in private funding, is aiming for a Hong Kong IPO in around 18 months......


查看全文→